anti-Tumor Necrosis Factor Receptor Superfamily, Member 6b, Decoy (TNFRSF6B) Anticorps

TNFRSF6B belongs to the tumor necrosis factor receptor superfamily. De plus, nous expédions TNFRSF6B Protéines (11) et TNFRSF6B Kits (6) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
TNFRSF6B 8771 O95407
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top anti-TNFRSF6B Anticorps sur

Showing 10 out of 89 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Humain Lapin Inconjugué IF, IHC, ELISA Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue, using TNFRSF6B Antibody. The picture on the right is treated with the synthesized peptide. Immunofluorescence analysis of HepG2 cells, using TNFRSF6B Antibody. The picture on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
Humain Lapin Inconjugué ELISA, ICC, IF, IHC, WB ABIN6266780 staining HeLa cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibody. ABIN6266780 at 1/100 staining human brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. 100 μL 11 to 12 Days
Humain Lapin Inconjugué ELISA, IF, IHC, WB 100 μL Disponible
Humain Lapin Inconjugué IHC, WB Western blot analysis of extracts of various cells, using TNFRSF6B antibody. 100 μL 11 to 13 Days
Humain Lapin Inconjugué EIA, IHC (p), WB TNFRSF6B antibody (N-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human colon carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the TNFRSF6B antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated. TNFRSF6B Antibody (N-term) western blot analysis in 293 cell line lysates (35 µg/lane). This demonstrates the TNFRSF6B antibody detected the TNFRSF6B protein (arrow). 0.4 mL 6 to 8 Days
Humain Souris Inconjugué ELISA, IHC, IHC (p), WB 100 μg 11 to 14 Days
Humain Lapin Inconjugué IHC, WB 0.1 mg 11 to 14 Days
Humain Lapin Inconjugué ELISA, IF, IHC (p), WB 200 μL 12 to 14 Days
Humain Lapin Inconjugué IF, IHC (p) Immunohistochemistry (IHC) analysis of DcR3 antibody in paraffin-embedded human colon carcinoma tissue. 0.1 mg 6 to 8 Days
Humain Lapin Inconjugué IHC (p), WB 0.1 mg 3 to 4 Days

anti-TNFRSF6B Anticorps mieux référencés

  1. Human Monoclonal TNFRSF6B Primary Antibody pour IHC (p), ELISA - ABIN563778 : Wu, Huang, Hsieh, Hsiao, Lee, Lin: EGFR-driven up-regulation of decoy receptor 3 in keratinocytes contributes to the pathogenesis of psoriasis. dans Biochimica et biophysica acta 2013 (PubMed)

Plus d’anticorps contre TNFRSF6B partenaires d’interaction

Human Tumor Necrosis Factor Receptor Superfamily, Member 6b, Decoy (TNFRSF6B) interaction partners

  1. significantly higher levels of TL1A and its decoy receptor DcR3 in RA patients than in controls; TL1A is significantly related to the disease activity and enhances IL-17 production

  2. Aberrant expression of DcR3, which is upregulated by oestrogen 25, is an important pathogenic factor in inducing endometriosis.

  3. High DCR3 expression is associated with coronary artery disease.

  4. Given the differential immune responses and evasion mechanisms in breast cancer, we expect to identify different breast cancer groups based on their expression of immune-related genes. TGF-beta and DcR3 are potential novel drug targets for breast cancer immunotherapy.

  5. The combination of decoy receptor 3, soluble urokinase type plasminogen activator receptor, and procalcitonin improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the efficiency of sepsis diagnosis.

  6. Compared with the control, miR-340 was significantly lower in the serum of hepatocellular carcinoma patients (p<0.01). miR-340 was lower in HCC tissues than in adjacent; however, DcR3, TGF-beta1 and Smad2 were higher.

  7. DcR3 treatment caused HepG2 cell cytoskeleton remodeling, inhibited E-cadherin expression, and promoted cell migration.

  8. DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma risk in Northeast Chinese females

  9. Study found that both transcriptional expression and post-transcriptional DcR3 expression DcR3 expression were significantly up-regulated in colorectal cancer (CRC) tissues. DcR3 was found to be playing a critical role in CRC proliferation and migration in vitro and in tumorigenesis and metastasis in vivo.

  10. Higher plasma DcR3 level was related to better coronary collateral circulation (CCC) formation and displayed potent predictive power for CCC status in patients with coronary artery disease.

  11. High serum DcR3 levels are associated with disease severity in nonatopic asthma patients.

  12. Results show that DcR3 engages TNF ligands: FasL, LIGHT, and TL1A in a structurally similar fashion and its promiscuity is due to recognition of backbone atoms and invariant side chains.

  13. These results raise the possibility for involvement of TL1A/DR3/DR3-mediated mechanisms in epithelial-mesenchymal interactions and the development of inflammation-induced intestinal fibrosis in Crohn's disease.

  14. when idiopathic pulmonary fibrosis cells interact with collagen matrix, aberrantly activated Akt increases DcR3 expression via GSK-3beta-NFATc1 and protects IPF cells from the FasL-dependent apoptotic pathway.

  15. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance.

  16. Loss of DcR3 impaired the growth and invasive property of HCC cell line of HepG2.

  17. Overexpression of DcR3 was significantly related to the risk of female reproductive cancers (OR=10.69, 95% CI: 6.33-18.05), TNM stage (OR=5.51, 95% CI: 2.83-10.71), differentiation (OR=4.16, 95% CI: 2.28-7.60), lymph node metastasis (OR=5.89, 95% CI: 3.16-10.9), age (OR=0.85, 95% CI: 0.51-1.44), and overall survival time (OR=1.84, 95% CI: 0.58-5.83).

  18. The serum level of DcR3 may be a useful marker for disease activity in ANCA-associated renal vasculitis.

  19. The sDcR3 levels in patients with HIV-1 subtype B were significantly higher than those in patients infected with subtype CRF01_AE. HIV-1 subtype B and slow disease progression were associated with higher levels of sDcR3.

  20. DcR3 inhibits influenza a virus-induced JNK and ERK activation in human macrophages

TNFRSF6B profil antigène

Profil protéine

This gene belongs to the tumor necrosis factor receptor superfamily. The encoded protein is postulated to play a regulatory role in suppressing FasL- and LIGHT-mediated cell death. It acts as a decoy receptor that competes with death receptors for ligand binding. Over-expression of this gene has been noted in gastrointestinal tract tumors. Read-through transcription into this gene from the neighboring upstream gene, which encodes regulator of telomere elongation helicase 1 (RTEL1), generates a non-coding transcript.

Gene names and symbols associated with TNFRSF6B

  • TNF receptor superfamily member 6b (TNFRSF6B) anticorps
  • tumor necrosis factor receptor superfamily, member 11b (tnfrsf11b) anticorps
  • regulator of telomere elongation helicase 1 (RTEL1) anticorps
  • TNF receptor superfamily member 6b (tnfrsf6b) anticorps
  • TNF receptor superfamily member 6b L homeolog (tnfrsf6b.L) anticorps
  • dcr3 anticorps
  • DJ583P15.1.1 anticorps
  • m68 anticorps
  • M68E anticorps
  • tr6 anticorps

Protein level used designations for TNFRSF6B

decoy receptor 3 , decoy receptor for Fas ligand , tumor necrosis factor receptor superfamily member 6B , tumor necrosis factor receptor superfamily, member 6b , tumor necrosis factor receptor superfamily, member 6b, decoy

8771 Homo sapiens
407674 Danio rerio
789154 Bos taurus
100024799 Monodelphis domestica
100145799 Xenopus (Silurana) tropicalis
100158264 Xenopus laevis
100221010 Taeniopygia guttata
Fournisseurs de qualité sélectionnés pour anti-TNFRSF6B (TNFRSF6B) Anticorps
Avez-vous cherché autre chose?